| 000 | 01681 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250518033013.0 | ||
| 264 | 0 | _c20190611 | |
| 008 | 201906s 0 0 eng d | ||
| 022 | _a1475-2840 | ||
| 024 | 7 |
_a10.1186/s12933-019-0853-x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aYang, Da-Ya | |
| 245 | 0 | 0 |
_aComparative outcomes of heart failure among existent classes of anti-diabetic agents: a network meta-analysis of 171,253 participants from 91 randomized controlled trials. _h[electronic resource] |
| 260 |
_bCardiovascular diabetology _c04 2019 |
||
| 300 |
_a47 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review | ||
| 650 | 0 | 4 |
_aCardiovascular Diseases _xdiagnosis |
| 650 | 0 | 4 |
_aDiabetes Mellitus _xdiagnosis |
| 650 | 0 | 4 |
_aDipeptidyl-Peptidase IV Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xadverse effects |
| 650 | 0 | 4 |
_aIncretins _xtherapeutic use |
| 650 | 0 | 4 | _aProtective Agents |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aSodium-Glucose Transporter 2 Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aHe, Xin | |
| 700 | 1 | _aLiang, Hui-Wei | |
| 700 | 1 | _aZhang, Shao-Zhao | |
| 700 | 1 | _aZhong, Xiang-Bin | |
| 700 | 1 | _aLuo, Chu-Fan | |
| 700 | 1 | _aDu, Zhi-Min | |
| 700 | 1 | _aHe, Jian-Gui | |
| 700 | 1 | _aZhuang, Xiao-Dong | |
| 700 | 1 | _aLiao, Xin-Xue | |
| 773 | 0 |
_tCardiovascular diabetology _gvol. 18 _gno. 1 _gp. 47 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/s12933-019-0853-x _zAvailable from publisher's website |
| 999 |
_c29565874 _d29565874 |
||